Abstract
Targeting hypoxia-induced signaling may extend the therapeutic benefit of enzalutamide, providing an improved treatment strategy for patients with resistant disease.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have